SABS SAB Biotherapeutics Inc
Company Analysis
Latest News
🟢 SAB Biotherapeutics is trading 5% up in pre-market amid pre-market biotech ETF strength
SAB Biotherapeutics is trading at $3.35, up 5.35%, amid a positive biotech-sector backdrop; no company-specific announcement has been confirmed. - Market...
🟢 SAB Biotherapeutics is trading 5% up today amid biotech-sector gains; specific catalyst unclear
SAB Biotherapeutics is trading at $3.29, up 5.45% on November 4, 2026; biotech-sector strength is a possible backdrop, but no specific cause for the additional...
🔴 SAB Biotherapeutics is trading 6.41% down in pre-market
SAB Biotherapeutics is trading at $2.92, down 6.41% in pre-market; no clear company-specific announcement explaining the decline was identified. - The company...
SAB Biotherapeutics Inc Q3 2026 Earnings Preview: What Analysts Expect on November 05, 2026
SAB Biotherapeutics is expected to report a Q3 2026 EPS loss of $0.27 on zero revenue, with the current stock price of $3.82 trading significantly below the...
🔴 SAB Biotherapeutics is trading 5% down with no company-specific explanation in available search results
SAB Biotherapeutics is trading 5% down now at $3.13, with no company-specific announcement explaining the November 3, 2026 decline found in available search...
🟢 SAB Biotherapeutics is trading 5% up in pre-market with no clear company-specific catalyst identified
SAB Biotherapeutics is trading at $3.40, up 5.26%, in pre-market, with no clear company-specific catalyst identified. - The latest company announcement...
🟢 SAB Biotherapeutics is trading 10.75% up in pre-market
SAB Biotherapeutics is trading at $3.40, up 10.75% in pre-market, with no clear company-specific catalyst identified for October 28. - The latest...
🟢 SAB Biotherapeutics is trading 10% up today
SAB Biotherapeutics is trading at $3.07, up 10.04%, with the move’s specific trigger still unclear. - Biotech shares were broadly higher, and supplied sector...
🟢 SAB Biotherapeutics is trading 6.3% up; no clear catalyst identified
SAB Biotherapeutics is trading 6.27% higher at $2.96 on October 27, 2026; the specific cause of the move remains unclear. - October 27 coverage discusses trial...
🔴 SAB Biotherapeutics is trading 14% down in pre-market — with no clear company-specific catalyst identified
SAB Biotherapeutics is trading at $2.40, down 13.98% in pre-market on October 27, with no clear company-specific catalyst identified. - Shares closed at $2.79...
🔴 SAB Biotherapeutics is trading 5.6% down today amid biotech sector weakness
SAB Biotherapeutics is trading at $2.87, down 5.59% on October 23, 2026, with biotech weakness a plausible contributor. - No clear company-specific catalyst...
🟢 SAB Biotherapeutics is trading 5% up today with no clear catalyst identified
SAB Biotherapeutics is trading at $2.97, up 5.32%, with no clear company-specific catalyst identified for the October 22 move. - The company’s...
🟢 SAB Biotherapeutics is trading 11% up today amid biotech-sector strength
SAB Biotherapeutics is trading at $2.88, up 10.58%, amid biotech-sector strength. - The provided market context reports the XBI up 2.10% during the regular...
🟢 SAB Biotherapeutics is trading 5.8% up today as biotech shares strengthen
SAB Biotherapeutics is trading at $2.75, up 5.77%, with broad biotech strength potentially supporting the move. - The XBI rose 2.10% during the regular...
🔴 SAB Biotherapeutics is trading 8.1% down in pre-market with no clear company-specific catalyst
SAB Biotherapeutics is trading at $2.39, down 8.08% in pre-market, with no clear company-specific announcement identified to explain the decline. - SAB...
🟢 SAB Biotherapeutics is trading 5.8% up in pre-market — reason remains unclear
SAB Biotherapeutics is trading at $2.74, up 5.79% in pre-market; the reason for the move remains unclear. - No October 16 company-specific catalyst was...
🔴 SAB Biotherapeutics is trading 5% down today; no clear company-specific catalyst reported
SAB Biotherapeutics is trading at $2.54, down 5.04%, with no clear company-specific catalyst reported. - October 13: FDA granted Fast Track designation for...
🟢 SAB Biotherapeutics is trading 8.8% up in pre-market
SAB Biotherapeutics is trading at $2.91, up 8.76% in pre-market; no clear reported catalyst for the rise was found. - The previous close was $2.68; supplied...
🔴 SAB Biotherapeutics is trading 5.5% down today amid biotech-sector weakness
SAB Biotherapeutics is trading at $2.67, down -5.48%, with biotech-sector weakness the clearest matching context. - The XBI is down 2.01% during the regular...
SABS Receives FDA Fast Track Designation for Type 1 Diabetes Therapy SAB-142
SAB Biotherapeutics announced it has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for its lead candidate, SAB-142. The...